EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Development and Validation of an 18 F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer

Zelda Paquier iD, Jennifer Dhont, Thomas Guiot iD, Hugo Levillain iD, Gabriela Critchi, Rita Saude Conde, Francesco Sclafani iD, Patrick Flamen, Nick Reynaert, Erwin Woff iD, Alain Hendlisz iD

JCO Clinical Cancer Informatics · 2025

DOI: 10.1200/cci-24-00207 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Zelda Paquier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Radiophysics and MRI Physics Laboratory, Université Libre De Bruxelles (ULB), Brussels, Belgium. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Life Expectancy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Managing chemorefractory metastatic colorectal cancer (mCRC) requires a meticulous equilibrium between the efficacy and toxicity of interventions, a task compounded by the constrained life expectancy of the patient. While existing prognostic tools, such as the Colon Life nomogram, primarily focus on general patient conditions or a single diagnostic modality, they do not fully integrate the potential predictive value of multimodal data. This study aims to develop and validate an Imaging Score, integrating clinical and imaging features derived from whole-body 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET-CT), predicting death probability within 12 weeks from treatment initiation for refractory disease. MATERIALS AND METHODS The development cohort comprises 254 patients from three clinical trials. Nine clinical variables and six imaging variables were assessed. After optimal subset selection through recursive Feature Elimination with cross-validation, a support vector classifier-trained machine learning model generated the Imaging Score. Validation was performed on a real-life patient cohort (n = 74). Model performance was assessed on discrimination (Harrell C-index) and calibration. RESULTS Final prognostic features included whole-body metabolically active tumor volume, Eastern Cooperative Oncology Group performance status, visceral fat density, number of metastatic sites, body mass index, maximum standardized distance, and months since diagnosis. The Imaging Score demonstrated robust discriminative ability in both the development (C-index, 0.797) and validation (C-index, 0.714) sets, outperforming the Colon Life nomogram that tended to overestimate 12-week mortality. CONCLUSION The Imaging Score, integrating 18 F-FDG PET-CT imaging with clinical parameters, is an effective prognostic tool for patients with chemorefractory mCRC. This combination of imaging biomarkers with clinical factors improves discrimination, enhancing its potential for clinical decision making, patient stratification for chemorefractory treatments, and trial eligibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyLife ExpectancyHumansMaleFemaleMiddle AgedPrognosisAgedRadiopharmaceuticalsNomogramsAged, 80 and overAdult

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Radiophysics and MRI Physics Laboratory, Université Libre De Bruxelles (ULB), Brussels, Belgium.
  • Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université libre de Bruxelles (ULB), Brussels, Belgium.
  • Department of Gastrointestinal Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université libre de Bruxelles (ULB), Brussels, Belgium.
  • Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université libre de Bruxelles (ULB), Brussels, Belgium.

ORCID-Profile: Zelda Paquier, Thomas Guiot, Hugo Levillain, Francesco Sclafani, Erwin Woff, Alain Hendlisz

Zitieren

APA

Paquier, Z., Dhont, J., Guiot, T., Levillain, H., Critchi, G., Saude Conde, R., Sclafani, F., Flamen, P., Reynaert, N., Woff, E., & Hendlisz, A. (2025). Development and Validation of an 18 F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00207

Vancouver

Paquier Z, Dhont J, Guiot T, Levillain H, Critchi G, Saude Conde R, et al. Development and Validation of an 18 F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00207

BibTeX
@article{Paquier2025,
  author = {Paquier, Zelda and Dhont, Jennifer and Guiot, Thomas and Levillain, Hugo and Critchi, Gabriela and Saude Conde, Rita and Sclafani, Francesco and Flamen, Patrick and Reynaert, Nick and Woff, Erwin and Hendlisz, Alain},
  title = {Development and Validation of an 18 F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  doi = {10.1200/cci-24-00207}
}
Kostenlos starten →